Extracorporeal magnetic approach to reduce the unwanted side‐effects and improve antibacterial activity of Ag/Fe3O4 nanocomposites in rat. Issue 5 (27th October 2017)

• Record Type: Journal Article
• Authors: Chen, Chao; Xia, Dong‐Lin; Guo, Ling‐Yan; Chen, Yan‐Pei; Li, Xiao‐Dong; Wang, Yu‐Fei; Zhang, Duo; Wang, Yu‐Ying; Zhang, Yu‐Xin; He, Hong; Gu, Hai‐Ying
• Is Part Of: Journal of biomedical materials research. Volume 106:Issue 5(2018)
• Page Start: 2029
• Page End: 2036
• Publication Date: 2017-10-27
• Subjects: Ag/Fe3O4 -- antibacterial activity -- wound healing -- biosafety; Biomedical materials -- Periodicals; 610.28
• DOI: 10.1002/jbm.b.33998
• Languages: English
• ISSNs: 1552-4973

Abstract

Abstract: While Ag nanoparticles hold great promise for broad spectrum antibacterial activity, the potential risks of Ag nanoparticles (NPs) on human health remain a challenge. In this study, Ag/Fe3 O4 composites have been successfully prepared and characterized by transmission electron microscopy, X‐ray powder diffraction, and Fourier‐transform infrared spectroscopy, and their magnetic and antibacterial properties have been assessed. In vivo results show that the antibacterial effect of 500 μg/mL Ag/Fe3 O4 nanocomposites was significantly higher than that of 1000 μg/mL AgNPs after 72 h of treatment ( p < 0.01). Hematoxylin and eosin (HE) staining showed that squamous epithelium and dermis collagen fibers formed in the Ag/Fe3 O4 group after 8 days treatment. Wound closure was significantly better for the Ag/Fe3 O4 group than for the AgNPs group. On the other hand, there was less Ag in blood, liver, and kidney in the Ag/Fe3 O4 group, as more Ag was retained in the wound. According to lactate dehydrogenase, γ‐glutamyl transpeptidase, and reactive oxygen species results, Ag/Fe3 O4 nanocomposites caused less unwanted side‐effects. This work presents a new paradigm to reduce the unwanted side‐effects of AgNPs and improve their antibacterial activity, providing a new avenue for wound healing. © 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 106B: 2029–2036, 2018.